VolitionRx Expands Accessibility with Launch of rNuQ Webshop for Researchers

VolitionRx Launches rNuQ™ Webshop

On April 20, 2026, VolitionRx Limited, a leading company in the field of epigenetics, announced the debut of its rNuQ webshop. This platform is designed to provide researchers with easy access to a diverse range of ready-to-use, recombinant nucleosomes that have been meticulously developed over the past decade.

About the rNuQ Webshop

VolitionRx's webshop is a significant step towards enhancing the accessibility of cutting-edge controls tailored for various research applications. The products available on the site are produced in a facility that meets ISO 13485 certifications, ensuring top-notch quality and reproducibility standards. This includes the storage and shipment of nucleosomes at +4 °C in a glycerol-free buffer, a method that not only simplifies handling but also preserves their structural integrity and performance in experiments.

According to Dr. Jasmine Kway, CEO of Volition, the webshop is part of a larger vision to commercialize their extensive range of epigenetic tools. The launch is part of their Nu.Q® Discover initiative, which currently serves nearly 100 worldwide clients, including major pharmaceutical and diagnostics companies. These collaborations have been pivotal, with some partners advancing to late-stage clinical trials while utilizing the assays developed by Volition as pharmacodynamic biomarkers.

Features of the rNuQ Nucleosomes

Researchers can browse an extensive portfolio, selecting nucleosomes based on specific requirements such as histone composition, post-translational modifications (PTMs), and unique citrullination patterns. This customization empowers scientists to tailor their experimental conditions precisely to their needs. The range also includes specially defined PTMs and engineered citrullination patterns, with certain exclusive nucleosomes, such as the H3K18 lactylation nucleosomes, unavailable from other sources.

Future Prospects and Revenue Growth

The establishment of the rNuQ webshop signifies not only an enhancement in product accessibility but also opens a new revenue stream for VolitionRx. As part of their ongoing development strategy, the company indicates that they are exploring bespoke assay developments for several pharmaceutical partners, expanding the applications of their nucleosomes from blood plasma to other biospecimens.

VolitionRx's previous year concluded with a remarkable 86% revenue growth within the Nu.Q® Discover segment. Expectations for 2026 suggest a continuation of this growth trajectory, as the company looks to solidify its position in the epigenetics market by providing high-quality research tools.

About VolitionRx

VolitionRx is dedicated to advancing the science of epigenetics with a mission to enhance the lives of individuals suffering from life-altering diseases through early detection and therapy monitoring. They are developing efficient and cost-effective blood tests aimed at detecting and monitoring various diseases, including certain cancers and conditions related to netosis. With a strong research and development base in Belgium and innovation labs in the U.S. and the U.K., VolitionRx continues to lead in the field of diagnostics.

For further queries, please contact Louise Batchelor at Volition.

In conclusion, the launch of the rNuQ webshop represents a transformative step for VolitionRx, providing increased availability of essential research tools and underscoring the company’s commitment to supporting the global medical research community.